Glycosaminoglycans enhance the trifluoroethanol-induced extension of beta 2-microglobulin-related amyloid fibrils at a neutral pH.

beta(2)-Microglobulin-related (A beta 2M) amyloidosis is a frequent and serious complication in patients on long-term dialysis, and beta(2)-microglobulin is a major structural component of A beta 2M amyloid fibrils. Several biologic molecules inhibiting the depolymerization of A beta 2M amyloid fibrils at a neutral pH were found recently. The effect of trifluoroethanol and glycosaminoglycans (GAG) on the extension of the fibrils at a neutral pH was investigated with the use of fluorescence spectroscopy with thioflavin T, circular dichroism spectroscopy, and electron microscopy. Trifluoroethanol at concentrations of up to 20% (vol/vol) caused fibril extension of heparin-stabilized seeds, inducing a subtle change in the tertiary structure of beta(2)-microglobulin and stabilizing the fibrils at a neutral pH. This extension reaction followed a first-order kinetic model. In addition, some GAG, especially heparin, dose-dependently enhanced the fibril extension. These results suggest that some GAG, especially heparin, may bind to the fibrils and enhance their deposition in vivo. Thus, the experimental system described here should be useful to search for the factors that accelerate A beta 2M amyloid deposition in vivo. In addition, the interference of the binding of GAG to A beta 2M amyloid fibrils may be an attractive therapeutic modality.

[1]  A. Webb,et al.  Maintaining blood flow in the extracorporeal circuit: haemostasis and anticoagulation , 2006, Intensive Care Medicine.

[2]  K. Ohashi,et al.  Proteoglycans in haemodialysis-related amyloidosis , 2004, Virchows Archiv.

[3]  F. Gejyo,et al.  Glycosaminoglycan and proteoglycan inhibit the depolymerization of beta2-microglobulin amyloid fibrils in vitro. , 2003, Kidney international.

[4]  D. Teplow,et al.  Kinetic Studies of Amyloid β-Protein Fibril Assembly , 2002, The Journal of Biological Chemistry.

[5]  M. Hoshino,et al.  Mapping the core of the β2-microglobulin amyloid fibril by H/D exchange , 2002, Nature Structural Biology.

[6]  K. Ohashi,et al.  Affinity Binding of Glycosaminoglycans with β2-Microglobulin , 2002, Nephron.

[7]  M. Hoshino,et al.  The intrachain disulfide bond of beta(2)-microglobulin is not essential for the immunoglobulin fold at neutral pH, but is essential for amyloid fibril formation at acidic pH. , 2002, Journal of biochemistry.

[8]  C. Dobson,et al.  A Partially Structured Species of β2-Microglobulin Is Significantly Populated under Physiological Conditions and Involved in Fibrillogenesis* , 2001, The Journal of Biological Chemistry.

[9]  D A Smith,et al.  Beta(2)-microglobulin and its deamidated variant, N17D form amyloid fibrils with a range of morphologies in vitro. , 2001, Journal of molecular biology.

[10]  N. Heegaard,et al.  Conformational Intermediate of the Amyloidogenic Protein β2-Microglobulin at Neutral pH* , 2001, The Journal of Biological Chemistry.

[11]  F. Gejyo,et al.  Apolipoprotein E inhibits the depolymerization of beta 2-microglobulin-related amyloid fibrils at a neutral pH. , 2001, Biochemistry.

[12]  C. Dobson,et al.  Detection of two partially structured species in the folding process of the amyloidogenic protein beta 2-microglobulin. , 2001, Journal of molecular biology.

[13]  F. Gejyo,et al.  Extension of Aβ2M amyloid fibrils with recombinant human β2-microglobulin , 2001 .

[14]  A. Koide,et al.  Solution conformation and amyloid-like fibril formation of a polar peptide derived from a beta-hairpin in the OspA single-layer beta-sheet. , 2000, Journal of molecular biology.

[15]  C. Dobson,et al.  Evidence concerning rate-limiting steps in protein folding from the effects of trifluoroethanol , 2000, Nature Structural Biology.

[16]  P. Fraser,et al.  Interactions of Alzheimer amyloid-beta peptides with glycosaminoglycans effects on fibril nucleation and growth. , 1999, European journal of biochemistry.

[17]  M. Jadoul,et al.  Histological characteristics of sternoclavicular beta 2-microglobulin amyloidosis and clues for its histogenesis. , 1999, Kidney international.

[18]  R. Kisilevsky,et al.  The Heparin/Heparan Sulfate-binding Site on Apo-serum Amyloid A , 1999, The Journal of Biological Chemistry.

[19]  M. Jadoul,et al.  Prevalence of histological beta2-microglobulin amyloidosis in CAPD patients compared with hemodialysis patients. , 1998, Kidney international.

[20]  M. Buck,et al.  Trifluoroethanol and colleagues: cosolvents come of age. Recent studies with peptides and proteins , 1998, Quarterly Reviews of Biophysics.

[21]  M. Judge,et al.  Sulfate content and specific glycosaminoglycan backbone of perlecan are critical for perlecan's enhancement of islet amyloid polypeptide (amylin) fibril formation. , 1998, Diabetes.

[22]  T. Wight,et al.  Perlecan Binds to the β‐Amyloid Proteins (Aβ) of Alzheimer's Disease, Accelerates Aβ Fibril Formation, and Maintains Aβ Fibril Stability , 1997 .

[23]  K. Ohashi,et al.  Visceral organ involvement and extracellular matrix changes in β2-microglobulin amyloidosis – a comparative study with systemic AA and AL amyloidosis , 1997, Virchows Archiv.

[24]  F. Gejyo,et al.  Concentration-dependent inhibitory effects of apolipoprotein E on Alzheimer's beta-amyloid fibril formation in vitro. , 1997, Biochemistry.

[25]  Satoru Suzuki,et al.  Establishment of a kinetic model of dialysis-related amyloid fibril extension in vitro , 1997 .

[26]  M. Skinner,et al.  Polymerization of normal and intact beta 2-microglobulin as the amyloidogenic protein in dialysis-amyloidosis. , 1996, Kidney international.

[27]  H. Naiki,et al.  First-order kinetic model of Alzheimer's beta-amyloid fibril extension in vitro. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[28]  P. Fraser,et al.  Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease , 1995, Nature Medicine.

[29]  K. Nishikawa,et al.  Trifluoroethanol-induced Stabilization of the α-Helical Structure of β-Lactoglobulin: Implication for Non-hierarchical Protein Folding , 1995 .

[30]  A. Davison.  beta 2-microglobulin and amyloidosis: who is at risk? , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[31]  F. Gejyo,et al.  A monoclonal antibody recognizing apolipoprotein E peptides in systemic amyloid deposits. , 1994, Annals of clinical and laboratory science.

[32]  P. Lansbury,et al.  Seeding “one-dimensional crystallization” of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie? , 1993, Cell.

[33]  M. Skinner,et al.  Demonstration of plasma proteinase inhibitors in beta 2-microglobulin amyloid deposits. , 1992, Kidney international.

[34]  M. Solé,et al.  In vitro spontaneous synthesis of beta 2-microglobulin amyloid fibrils in peripheral blood mononuclear cell culture. , 1992, The American journal of pathology.

[35]  K. Ohashi,et al.  Cervical discs are most susceptible to beta 2-microglobulin amyloid deposition in the vertebral column. , 1992, Kidney international.

[36]  K. Koch,et al.  Dialysis-related amyloidosis. , 1992, Kidney international.

[37]  R. Bramson,et al.  A temporal and ultrastructural relationship between heparan sulfate proteoglycans and AA amyloid in experimental amyloidosis. , 1991, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[38]  K. Higuchi,et al.  Kinetic analysis of amyloid fibril polymerization in vitro. , 1991, Laboratory investigation; a journal of technical methods and pathology.

[39]  B. Maldague,et al.  Effect of dialysis membrane and patient's age on signs of dialysis-related amyloidosis. The Working Party on Dialysis Amyloidosis. , 1991, Kidney international.

[40]  F. Gejyo,et al.  Dialysis amyloidosis: current disease concepts and new perspectives for its treatment. , 1990, Contributions to nephrology.

[41]  M. Skinner,et al.  Glycosaminoglycans of the hemodialysis-associated carpal synovial amyloid and of amyloid-rich tissues and fibrils of heart, liver, and spleen. , 1990, Clinical chemistry.

[42]  O. Toupance,et al.  Carpal tunnel syndrome and type of dialysis membrane. , 1989, BMJ.

[43]  C. Kay,et al.  Circular-dichroism studies on two murine serum amyloid A proteins. , 1988, The Biochemical journal.

[44]  B. Frangione,et al.  Polymerization of intact beta 2-microglobulin in tissue causes amyloidosis in patients on chronic hemodialysis. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[45]  F. Gejyo,et al.  Serum levels of beta 2-microglobulin as a new form of amyloid protein in patients undergoing long-term hemodialysis. , 1986, The New England journal of medicine.

[46]  P. K. Smith,et al.  Measurement of protein using bicinchoninic acid. , 1985, Analytical biochemistry.

[47]  M Arakawa,et al.  A new form of amyloid protein associated with chronic hemodialysis was identified as beta 2-microglobulin. , 1985, Biochemical and biophysical research communications.

[48]  B. Charra,et al.  Carpal tunnel syndrome, shoulder pain and amyloid deposits in long-term haemodialysis patients. , 1985, Proceedings of the European Dialysis and Transplant Association - European Renal Association. European Dialysis and Transplant Association - European Renal Association. Congress.

[49]  R W Farndale,et al.  A direct spectrophotometric microassay for sulfated glycosaminoglycans in cartilage cultures. , 1982, Connective tissue research.